Novo Nordisk's CEO, Mike Doustdar, stated in a CNBC interview that the company is more active than ever in seeking out business development deals and acquisitions, aiming to broaden its pipeline to help hundreds of millions of patients globally [1]. Doustdar emphasized the company's ambition to not only have the best but also the broadest pipeline in the industry, highlighting ongoing and future acquisition activities [1].
The CEO addressed analyst concerns regarding the robustness of Novo Nordisk's pipeline, especially as competition in the obesity drug market intensifies. While Eli Lilly has surpassed Novo Nordisk in market share for weekly GLP-1 shots, Novo Nordisk has established an early lead in the emerging GLP-1 pill category for weight loss [1]. Doustdar expressed confidence in the company's pipeline, specifically mentioning CagriSema—a drug candidate targeting GLP-1 and amylin, which Novo hopes will be approved by the end of the year—and zenagamtide, an experimental amylin-targeting drug that has seen accelerated development [1].
Doustdar also noted that there are additional promising assets in the pipeline that have not yet been publicly disclosed, urging skeptical investors to "wait and see" [1]. The interview followed Novo Nordisk's announcement that its Wegovy pill outperformed expectations in the first quarter, prompting the company to raise its full-year profit guidance [1].
No specific market reactions or analyst opinions beyond the CEO's statements were provided in the article.
CONCLUSION
Novo Nordisk is intensifying its pursuit of deals and acquisitions to expand its drug pipeline, with the CEO expressing strong confidence in upcoming treatments and ongoing development efforts. The company's recent performance and raised profit guidance underscore its positive outlook, despite competitive pressures in the obesity drug market.